Table 1.
The current basis for prognostication of acute myeloid leukemia (AML) patients.
| Prognostic Factors | Reference(s) |
|---|---|
| Circulating blast cells at the time of diagnosis | [49] |
| Karyotype | [12] |
| Molecular genetics | [12] |
| Secondary AML | [50] |
| Metabolic status at the time of diagnosis | [51] |
| AML subclones at the time of diagnosis | [52,53,54] |
| No remaining blasts on light microscopy 14–17 days after start of induction chemotherapy | [55] |
| Complete hematological remission after first induction cycle | [49] |
| MRD after consolidation | [56,57] |
| Time of relapse: - After conventional therapy (i.e., duration of first complete remission) |
[58,59] |
| - Time from ASCT until diagnosis of relapse | [60,61] |
MRD: minimal residual disease; ASCT: allogeneic stem cell transplantation.